HC-030031, TRPA1 blocker (ab120554)
Key features and details
- TRPA1 blocker, orally active
- CAS Number: 349085-38-7
- Soluble in DMSO to 100 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
HC-030031, TRPA1 blocker -
Description
TRPA1 blocker, orally active -
Biological description
Selective TRPA1 blocker, orally active. Blocks TRPA1-mediated currents (IC50 = 0.7 μM) and selective over TRPV1, TRPV3, TRPV4, hERG, and NaV1.2 channels (IC50 >10 μM). Does not display any significant binding to 41 other receptors, ion channels, and transporters nor functional modulation of 7 enzymes that are known to modulate pain signaling.
-
CAS Number
349085-38-7 -
Chemical structure
Properties
-
Chemical name
2-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide -
Molecular weight
355.40 -
Molecular formula
C18H21N5O3 -
PubChem identifier
1150897 -
Storage instructions
Store at Room Temperature. The product can be stored for up to 12 months. -
Solubility overview
Soluble in DMSO to 100 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Toxic, refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
CC(C)c1ccc(cc1)NC(=O)Cn3cnc2c3C(=O)N(C)C(=O)N2C -
Source
Synthetic
-
Research areas
Images
-
Chemical Structure - HC-030031, TRPA1 blocker (ab120554)2D chemical structure image of ab120554, HC-030031, TRPA1 blocker
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (6)
ab120554 has been referenced in 6 publications.
- Shalev N et al. Phytocannabinoid Compositions from Cannabis Act Synergistically with PARP1 Inhibitor against Ovarian Cancer Cells In Vitro and Affect the Wnt Signaling Pathway. Molecules 27:N/A (2022). PubMed: 36364346
- Anil SM et al. Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages. Sci Rep 11:1462 (2021). PubMed: 33446817
- Anis O et al. Cannabis-Derived Compounds Cannabichromene and ?9-Tetrahydrocannabinol Interact and Exhibit Cytotoxic Activity against Urothelial Cell Carcinoma Correlated with Inhibition of Cell Migration and Cytoskeleton Organization. Molecules 26:N/A (2021). PubMed: 33477303
- Peeri H et al. Specific Compositions of Cannabis sativa Compounds Have Cytotoxic Activity and Inhibit Motility and Colony Formation of Human Glioblastoma Cells In Vitro. Cancers (Basel) 13:N/A (2021). PubMed: 33916466
- Masuoka T et al. TRPA1 Channels Modify TRPV1-Mediated Current Responses in Dorsal Root Ganglion Neurons. Front Physiol 8:272 (2017). PubMed: 28515697
- White BJ et al. Hydrogen sulphide-mediated vasodilatation involves the release of neurotransmitters from sensory nerves in pressurized mesenteric small arteries isolated from rats. Br J Pharmacol 168:785-93 (2013). PubMed: 22928888